✦ LIBER ✦

A Randomized, Placebo-Controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately to Severely Active Ulcerative Colitis

✍ Scribed by Lloyd Mayer; William J. Sandborn; Yuriy Stepanov; Judith Maccarone; Xiaolu Tao; Li-An Lu; Sheila Gujrathi; Richard Aranda; Allison Luo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daclizumab, a humanised monoclonal antib

✍ Van Assche, G; Sandborn, W J; Feagan, B G; Salzberg, B A; Silvers, D; Monroe, P 📂 Article 📅 2006 🏛 BMJ Publishing Group 🌐 English ⚖ 1010 KB

865 Phase IIB, Randomized, Placebo-Contr

✍ Sandborn, William J.; Colombel, Jean-Frederic; Ghosh, Subrata; Sands, Bruce E.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 392 KB

P547 Biological agents for moderately-to

✍ Danese, S.; Fiorino, G.; Peyrin-Biroulet, L.; Lucenteforte, E.; Virgili, G.; Moj 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 48 KB

701 A Randomized, Double-Blind, Placebo-

✍ Govind K. Makharia; Ajit Sood; Vandana Midha; Vineet Ahuja; Dinesh K. Singal; Re 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 94 KB

A randomized, double-blind, placebo-cont

✍ Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB